<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386475</url>
  </required_header>
  <id_info>
    <org_study_id>SELEIS</org_study_id>
    <secondary_id>2014-000846-32</secondary_id>
    <nct_id>NCT02386475</nct_id>
  </id_info>
  <brief_title>Effect of Serotonin and Levodopa in Ischemic Stroke</brief_title>
  <acronym>SELEIS</acronym>
  <official_title>Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Granollers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Granollers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cortical plasticity plays a pivotal role in functional recovery after a stroke.
      Neurotransmitter release, facilitates the creation of new synapses and promotes brain
      plasticity. In a pilot study, will evaluate the potential benefit of drugs that increase the
      release of neurotransmitters in patients with first stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods. Evaluate 240 consecutive patients with a first ischemic stroke with NIHSS 5-20
      without aphasia and with a previous independent functional status (mRS &lt;3). Patients will be
      randomized into four arms: 1) control group, 2) treatment with citalopram 20 mg / day, 3)
      group levodopa (sinemet plus)100 mg / day, 4) group levodopa (sinemet plus) 100 mg / day +
      citalopram 20 mg / day.

      The treatment begins within the first 5 days of stroke and is maintained for 6 months. All
      patients will be treated according to current guidelines for secondary prevention. We will
      assess the following variables: demographic, vascular risk factors, etiologic subtypes
      according to TOAST criteria, neurologic deficit with the NIHSS scale, cognitive assessment
      with Minimental scale and functional status with scale modified Rankin at discharge, 3, 6 and
      12 months, Symbol Digit Modalities Test (SDMT), GDS-15 Geriatric Depression Scale, Logical
      memory of WMS-IV . The cognitive assessment and motor functional status will be evaluated by
      a neuropsychologist and neurologist blinded to treatment assignment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rankin Scale</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>citalopram 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sinemet plus 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sinemet Plus + citalopram group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>control group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citalopram</intervention_name>
    <description>In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.</description>
    <arm_group_label>citalopram 20 mg</arm_group_label>
    <arm_group_label>Sinemet Plus + citalopram group</arm_group_label>
    <other_name>citalopram group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sinemet plus</intervention_name>
    <description>In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.</description>
    <arm_group_label>sinemet plus 100 mg</arm_group_label>
    <arm_group_label>Sinemet Plus + citalopram group</arm_group_label>
    <other_name>sinemet group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Patients with a first stroke with NIHSS 5-20 points

               -  Patients without aphasia to avoid interference in the assessment of depression
                  and cognitive impairment

               -  Patients with independent functional status prior to stroke (mRS &lt;3)

               -  Patients without prior cognitive impairment or depressive syndrome assessed by
                  medical history with the patient and family.

               -  The assigned treatment initiated within the first five days of stroke

        Exclusion Criteria:

          -  • Patients with prior myocardial or cerebral hemorrhage

               -  Patients with TIA

               -  Patients with aphasia

               -  History of cognitive impairment or prior depressive syndrome

               -  Patients with no independent functional status mRS greater than or equal to 3

               -  Underlying disease hopefully less than one year of life.

               -  Patient pre-treatment with levodopa, an antidepressant or neuroleptic.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dolores Cocho</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Granollers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dolores Cocho</last_name>
    <phone>938425000</phone>
    <email>dcocho@fhag.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Granollers General Hospital</name>
      <address>
        <city>Granollers</city>
        <state>Barcelnoa</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Cocho, M.D.</last_name>
      <phone>938425000</phone>
      <email>dcocho@fhag.es</email>
    </contact>
    <contact_backup>
      <last_name>diana navarro, Ph. D.</last_name>
      <phone>938425000</phone>
      <email>diananavarro@fhag.es</email>
    </contact_backup>
    <investigator>
      <last_name>Dolores Cocho, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA. Stroke incidence on the east coast of Australia: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2000 Sep;31(9):2087-92.</citation>
    <PMID>10978034</PMID>
  </reference>
  <reference>
    <citation>Bruel-Jungerman E, Rampon C, Laroche S. Adult hippocampal neurogenesis, synaptic plasticity and memory: facts and hypotheses. Rev Neurosci. 2007;18(2):93-114. Review.</citation>
    <PMID>17593874</PMID>
  </reference>
  <reference>
    <citation>Jin K, Minami M, Lan JQ, Mao XO, Batteur S, Simon RP, Greenberg DA. Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4710-5.</citation>
    <PMID>11296300</PMID>
  </reference>
  <reference>
    <citation>Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med. 2002 Sep;8(9):963-70. Epub 2002 Aug 5.</citation>
    <PMID>12161747</PMID>
  </reference>
  <reference>
    <citation>Yamashita T, Ninomiya M, Hernández Acosta P, García-Verdugo JM, Sunabori T, Sakaguchi M, Adachi K, Kojima T, Hirota Y, Kawase T, Araki N, Abe K, Okano H, Sawamoto K. Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the post-stroke adult striatum. J Neurosci. 2006 Jun 14;26(24):6627-36.</citation>
    <PMID>16775151</PMID>
  </reference>
  <reference>
    <citation>Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, Greenberg DA. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest. 2003 Jun;111(12):1843-51.</citation>
    <PMID>12813020</PMID>
  </reference>
  <reference>
    <citation>Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, Rascol O, Chollet F. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001 Dec;50(6):718-29.</citation>
    <PMID>11761469</PMID>
  </reference>
  <reference>
    <citation>Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res. 2009 Mar;87(4):1037-45. doi: 10.1002/jnr.21899.</citation>
    <PMID>18855941</PMID>
  </reference>
  <reference>
    <citation>Ruscher K, Kuric E, Wieloch T. Levodopa treatment improves functional recovery after experimental stroke. Stroke. 2012 Feb;43(2):507-13. doi: 10.1161/STROKEAHA.111.638767. Epub 2011 Nov 17.</citation>
    <PMID>22096034</PMID>
  </reference>
  <reference>
    <citation>Gu Q. Neuromodulatory transmitter systems in the cortex and their role in cortical plasticity. Neuroscience. 2002;111(4):815-35. Review.</citation>
    <PMID>12031406</PMID>
  </reference>
  <reference>
    <citation>Costa RM. Plastic corticostriatal circuits for action learning: what's dopamine got to do with it? Ann N Y Acad Sci. 2007 May;1104:172-91. Epub 2007 Apr 13. Review.</citation>
    <PMID>17435119</PMID>
  </reference>
  <reference>
    <citation>Jacobs BL, Fornal CA. Serotonin and motor activity. Curr Opin Neurobiol. 1997 Dec;7(6):820-5. Review.</citation>
    <PMID>9464975</PMID>
  </reference>
  <reference>
    <citation>Martinsson L, Hårdemark H, Eksborg S. Amphetamines for improving recovery after stroke. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002090. Review.</citation>
    <PMID>17253474</PMID>
  </reference>
  <reference>
    <citation>Treig T, Werner C, Sachse M, Hesse S. No benefit from D-amphetamine when added to physiotherapy after stroke: a randomized, placebo-controlled study. Clin Rehabil. 2003 Sep;17(6):590-9.</citation>
    <PMID>12971703</PMID>
  </reference>
  <reference>
    <citation>Platz T, Kim IH, Engel U, Pinkowski C, Eickhof C, Kutzner M. Amphetamine fails to facilitate motor performance and to enhance motor recovery among stroke patients with mild arm paresis: interim analysis and termination of a double blind, randomised, placebo-controlled trial. Restor Neurol Neurosci. 2005;23(5-6):271-80.</citation>
    <PMID>16477089</PMID>
  </reference>
  <reference>
    <citation>Gladstone DJ, Danells CJ, Armesto A, McIlroy WE, Staines WR, Graham SJ, Herrmann N, Szalai JP, Black SE; Subacute Therapy with Amphetamine and Rehabilitation for Stroke Study Investigators. Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial. Stroke. 2006 Jan;37(1):179-85. Epub 2005 Dec 1.</citation>
    <PMID>16322487</PMID>
  </reference>
  <reference>
    <citation>Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, Jaillard A, Niclot P, Guillon B, Moulin T, Marque P, Pariente J, Arnaud C, Loubinoux I. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb;10(2):123-30. doi: 10.1016/S1474-4422(10)70314-8. Epub 2011 Jan 7. Erratum in: Lancet Neurol. 2011 Mar;10(3):205.</citation>
    <PMID>21216670</PMID>
  </reference>
  <reference>
    <citation>Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. Stroke. 2000 May;31(5):1062-8.</citation>
    <PMID>10797166</PMID>
  </reference>
  <reference>
    <citation>Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil. 1998 Sep;79(9):1047-50.</citation>
    <PMID>9749682</PMID>
  </reference>
  <reference>
    <citation>Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, Curdue K, Petracca G, Starkstein SE. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000 Mar;157(3):351-9.</citation>
    <PMID>10698809</PMID>
  </reference>
  <reference>
    <citation>Bilge C, Koçer E, Koçer A, Türk Börü U. Depression and functional outcome after stroke: the effect of antidepressant therapy on functional recovery. Eur J Phys Rehabil Med. 2008 Mar;44(1):13-8.</citation>
    <PMID>18385623</PMID>
  </reference>
  <reference>
    <citation>Saxena SK, Ng TP, Koh G, Yong D, Fong NP. Is improvement in impaired cognition and depressive symptoms in post-stroke patients associated with recovery in activities of daily living? Acta Neurol Scand. 2007 May;115(5):339-46.</citation>
    <PMID>17489945</PMID>
  </reference>
  <reference>
    <citation>Sonde L, Lökk J. Effects of amphetamine and/or L-dopa and physiotherapy after stroke - a blinded randomized study. Acta Neurol Scand. 2007 Jan;115(1):55-9.</citation>
    <PMID>17156266</PMID>
  </reference>
  <reference>
    <citation>Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, Freo U, Piron L, Battistin L. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996 Jul;27(7):1211-4.</citation>
    <PMID>8685930</PMID>
  </reference>
  <reference>
    <citation>Yan T, Hui-Chan CW, Li LS. Functional electrical stimulation improves motor recovery of the lower extremity and walking ability of subjects with first acute stroke: a randomized placebo-controlled trial. Stroke. 2005 Jan;36(1):80-5. Epub 2004 Nov 29.</citation>
    <PMID>15569875</PMID>
  </reference>
  <reference>
    <citation>Cooke EV, Mares K, Clark A, Tallis RC, Pomeroy VM. The effects of increased dose of exercise-based therapies to enhance motor recovery after stroke: a systematic review and meta-analysis. BMC Med. 2010 Oct 13;8:60. doi: 10.1186/1741-7015-8-60. Review.</citation>
    <PMID>20942915</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

